Clinical Trials
112 trialsBipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
ASCLEPIuS
University of Michigan Rogel Cancer Center
DIVINE
Mayo Clinic
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
THUNDER
Cancer Research Antwerp
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Rezvilutamide for High-Risk Prostate Cancer After Surgery
Fujian Medical University Union Hospital
ARCH
University of Colorado, Denver
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
REVELUTION
Emory University
COAction
Brazilian Clinical Research Institute
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
CASPAR
Alliance for Clinical Trials in Oncology
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NYU Langone Health
NePtune
Hoosier Cancer Research Network
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
STEEL
RTOG Foundation, Inc.
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
M.D. Anderson Cancer Center
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Dana-Farber Cancer Institute
CARLHA-2
UNICANCER
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
READT
Chinese University of Hong Kong
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Columbia University
ADOPT
University Medical Center Groningen
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Ottawa Hospital Research Institute
The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient
Sir Mortimer B. Davis - Jewish General Hospital
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Neoadjuvant Ipilimumab in Prostate Cancer
M.D. Anderson Cancer Center
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SAVE
Cancer Research Antwerp
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
ACDC-RP
University Health Network, Toronto
URONCOR 06-24
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic